Table 1.
Decline in VC and %VC at week 52 in subpopulations characterized by baseline %VC and the lowest SpO2
| Item | Category 1 SpO2 |
Category 2 Baseline %VC |
High-dose Group | Low-dose Group | Placebo Group | P-value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LS mean (n) | SE | LS mean (n) | SE | LS mean (n) | SE | H vs P | L vs P | H+L vs P | |||
| Change in VC |
6MWT SpO2≥90 |
%VC≥70 | -0.072 (35) | 0.033 | -0.004 (16) | 0.050 | -0.090 (32) | 0.035 | 0.7035 | 0.1595 | 0.2581 |
| %VC<70 | -0.263 (9) | 0.073 | -0.185 (6) | 0.090 | -0.225 (9) | 0.073 | 0.7181 | 0.7350 | 0.9919 | ||
| 6MWT SpO2<90 |
%VC≥70 | -0.050 (36) | 0.049 | -0.016 (17) | 0.071 | -0.199 (36) | 0.049 | 0.0359 | 0.0372 | 0.0131 | |
| %VC<70 | -0.148 (23) | 0.051 | -0.181 (15) | 0.062 | -0.168 (26) | 0.048 | 0.7768 | 0.8735 | 0.9539 | ||
| Change in %VC |
6MWT SpO2≥90 |
%VC≥70 | -2.083 (35) | 1.070 | -0.420 (16) | 1.580 | -2.801 (32) | 1.114 | 0.6438 | 0.2209 | 0.2927 |
| %VC<70 | -9.084 (9) | 2.446 | -7.340 (6) | 2.963 | -7.167 (9) | 2.449 | 0.5902 | 0.9647 | 0.7427 | ||
| 6MWT SpO2<90 |
%VC≥70 | -1.737 (36) | 1.569 | -0.590 (17) | 2.264 | -6.080 (36) | 1.568 | 0.0555 | 0.0493 | 0.0213 | |
| %VC<70 | -4.143 (23) | 1.637 | -5.090 (15) | 2.079 | -5.669 (26) | 1.567 | 0.5037 | 0.8280 | 0.6158 | ||